Management of Post-transplant Hyperparathyroidism and Bone Disease
Significant advances in immunosuppressive therapies have been made in renal transplantation, leading to increased allograft and patient survival. Despite improvement in overall patient survival, patients continue to require management of persistent post-transplant hyperparathyroidism. Medications th...
Gespeichert in:
| Veröffentlicht in: | Drugs (New York, N.Y.) N.Y.), 2019-04, Vol.79 (5), p.501-513 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 513 |
|---|---|
| container_issue | 5 |
| container_start_page | 501 |
| container_title | Drugs (New York, N.Y.) |
| container_volume | 79 |
| creator | Delos Santos, Rowena Rossi, Ana Coyne, Daniel Maw, Thin Thin |
| description | Significant advances in immunosuppressive therapies have been made in renal transplantation, leading to increased allograft and patient survival. Despite improvement in overall patient survival, patients continue to require management of persistent post-transplant hyperparathyroidism. Medications that treat persistent hyperparathyroidism include vitamin D, vitamin D analogues, and calcimimetics. Medication side effects such as hypocalcemia or hypercalcemia, and adynamic bone disease, may lead to a decrease in the drugs. When medical management fails to control persistent post-transplant hyperparathyroidism, treatment is a parathyroidectomy. Surgical techniques are not uniform between centers and surgeons. Undergoing the surgery may include a subtotal technique or a technique including total parathyroid gland resection with partial heterotopic gland reimplantation. In addition, there are possible post-surgical complications. The ideal treatment for persistent post-transplant hyperparathyroidism is the treatment and prevention of the condition while patients are being managed for their late-stage chronic kidney disease and end-stage renal disease. |
| doi_str_mv | 10.1007/s40265-019-01074-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6439149</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2186623738</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-d3c3a7258a1601a6bb9688c71d19b712b5d5ebe4009d152bf3804f95e5dbe5703</originalsourceid><addsrcrecordid>eNp9kU1P3DAQhq2qFWyBP9BDFakXLikz_owvlQqUD4kKDvRsOclkCdrEqZ1F2n-P6VJaeujBssbzzOt59TL2AeEzApijJIFrVQLafMDIUr5hC0RjS7QK3rIFAPJSa2122fuU7p9Kq-wO2xVQIeZqwY6_-9EvaaBxLkJX3IQ0l3P0Y5pWPj9dbCaKk49-vtvE0Ld9Ggo_tsVxGKk47RP5RPvsXedXiQ6e7z324-zb7clFeXV9fnny9apspJFz2YpGeMNV5VEDel3XVldVY7BFWxvktWoV1SQBbIuK152oQHZWkWprUgbEHvuy1Z3W9UBtk1eOfuWm2A8-blzwvXvdGfs7twwPTkthUdoscPgsEMPPNaXZDX1qaJWdUlgnx7HSmgsjqox--ge9D-s4ZnuOZwtgQXOTKb6lmhhSitS9LIPgniJy24hcjsj9isjJPPTxbxsvI78zyYDYAim3xiXFP3__R_YRMcmcOA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2258090627</pqid></control><display><type>article</type><title>Management of Post-transplant Hyperparathyroidism and Bone Disease</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Delos Santos, Rowena ; Rossi, Ana ; Coyne, Daniel ; Maw, Thin Thin</creator><creatorcontrib>Delos Santos, Rowena ; Rossi, Ana ; Coyne, Daniel ; Maw, Thin Thin</creatorcontrib><description>Significant advances in immunosuppressive therapies have been made in renal transplantation, leading to increased allograft and patient survival. Despite improvement in overall patient survival, patients continue to require management of persistent post-transplant hyperparathyroidism. Medications that treat persistent hyperparathyroidism include vitamin D, vitamin D analogues, and calcimimetics. Medication side effects such as hypocalcemia or hypercalcemia, and adynamic bone disease, may lead to a decrease in the drugs. When medical management fails to control persistent post-transplant hyperparathyroidism, treatment is a parathyroidectomy. Surgical techniques are not uniform between centers and surgeons. Undergoing the surgery may include a subtotal technique or a technique including total parathyroid gland resection with partial heterotopic gland reimplantation. In addition, there are possible post-surgical complications. The ideal treatment for persistent post-transplant hyperparathyroidism is the treatment and prevention of the condition while patients are being managed for their late-stage chronic kidney disease and end-stage renal disease.</description><identifier>ISSN: 0012-6667</identifier><identifier>ISSN: 1179-1950</identifier><identifier>EISSN: 1179-1950</identifier><identifier>DOI: 10.1007/s40265-019-01074-4</identifier><identifier>PMID: 30811012</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Bone diseases ; Bone Diseases - etiology ; Bone Diseases - prevention & control ; Bone Diseases - therapy ; Calciferol ; Calcimimetic Agents - therapeutic use ; Complications ; Disease control ; End-stage renal disease ; Hemodialysis ; Homeostasis ; Humans ; Hypercalcemia ; Hyperparathyroidism ; Hyperparathyroidism - etiology ; Hyperparathyroidism - prevention & control ; Hyperparathyroidism - therapy ; Hyperparathyroidism, Secondary - etiology ; Hypocalcemia ; Immunoassay ; Immunosuppressive agents ; Internal Medicine ; Kidney diseases ; Kidney transplantation ; Kidney Transplantation - adverse effects ; Lead ; Management ; Medical personnel ; Medicine ; Medicine & Public Health ; Parathyroid ; Parathyroid gland ; Parathyroidectomy ; Patients ; Pharmacology/Toxicology ; Pharmacotherapy ; Side effects ; Surgery ; Survival ; Therapy in Practice ; Transplantation ; Transplantation, Homologous ; Transplants & implants ; Treatment Outcome ; Vitamin D ; Vitamin D - therapeutic use</subject><ispartof>Drugs (New York, N.Y.), 2019-04, Vol.79 (5), p.501-513</ispartof><rights>The Author(s) 2019</rights><rights>Copyright Springer Nature B.V. Apr 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-d3c3a7258a1601a6bb9688c71d19b712b5d5ebe4009d152bf3804f95e5dbe5703</citedby><cites>FETCH-LOGICAL-c474t-d3c3a7258a1601a6bb9688c71d19b712b5d5ebe4009d152bf3804f95e5dbe5703</cites><orcidid>0000-0002-8844-6925</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40265-019-01074-4$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40265-019-01074-4$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30811012$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Delos Santos, Rowena</creatorcontrib><creatorcontrib>Rossi, Ana</creatorcontrib><creatorcontrib>Coyne, Daniel</creatorcontrib><creatorcontrib>Maw, Thin Thin</creatorcontrib><title>Management of Post-transplant Hyperparathyroidism and Bone Disease</title><title>Drugs (New York, N.Y.)</title><addtitle>Drugs</addtitle><addtitle>Drugs</addtitle><description>Significant advances in immunosuppressive therapies have been made in renal transplantation, leading to increased allograft and patient survival. Despite improvement in overall patient survival, patients continue to require management of persistent post-transplant hyperparathyroidism. Medications that treat persistent hyperparathyroidism include vitamin D, vitamin D analogues, and calcimimetics. Medication side effects such as hypocalcemia or hypercalcemia, and adynamic bone disease, may lead to a decrease in the drugs. When medical management fails to control persistent post-transplant hyperparathyroidism, treatment is a parathyroidectomy. Surgical techniques are not uniform between centers and surgeons. Undergoing the surgery may include a subtotal technique or a technique including total parathyroid gland resection with partial heterotopic gland reimplantation. In addition, there are possible post-surgical complications. The ideal treatment for persistent post-transplant hyperparathyroidism is the treatment and prevention of the condition while patients are being managed for their late-stage chronic kidney disease and end-stage renal disease.</description><subject>Bone diseases</subject><subject>Bone Diseases - etiology</subject><subject>Bone Diseases - prevention & control</subject><subject>Bone Diseases - therapy</subject><subject>Calciferol</subject><subject>Calcimimetic Agents - therapeutic use</subject><subject>Complications</subject><subject>Disease control</subject><subject>End-stage renal disease</subject><subject>Hemodialysis</subject><subject>Homeostasis</subject><subject>Humans</subject><subject>Hypercalcemia</subject><subject>Hyperparathyroidism</subject><subject>Hyperparathyroidism - etiology</subject><subject>Hyperparathyroidism - prevention & control</subject><subject>Hyperparathyroidism - therapy</subject><subject>Hyperparathyroidism, Secondary - etiology</subject><subject>Hypocalcemia</subject><subject>Immunoassay</subject><subject>Immunosuppressive agents</subject><subject>Internal Medicine</subject><subject>Kidney diseases</subject><subject>Kidney transplantation</subject><subject>Kidney Transplantation - adverse effects</subject><subject>Lead</subject><subject>Management</subject><subject>Medical personnel</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Parathyroid</subject><subject>Parathyroid gland</subject><subject>Parathyroidectomy</subject><subject>Patients</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacotherapy</subject><subject>Side effects</subject><subject>Surgery</subject><subject>Survival</subject><subject>Therapy in Practice</subject><subject>Transplantation</subject><subject>Transplantation, Homologous</subject><subject>Transplants & implants</subject><subject>Treatment Outcome</subject><subject>Vitamin D</subject><subject>Vitamin D - therapeutic use</subject><issn>0012-6667</issn><issn>1179-1950</issn><issn>1179-1950</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kU1P3DAQhq2qFWyBP9BDFakXLikz_owvlQqUD4kKDvRsOclkCdrEqZ1F2n-P6VJaeujBssbzzOt59TL2AeEzApijJIFrVQLafMDIUr5hC0RjS7QK3rIFAPJSa2122fuU7p9Kq-wO2xVQIeZqwY6_-9EvaaBxLkJX3IQ0l3P0Y5pWPj9dbCaKk49-vtvE0Ld9Ggo_tsVxGKk47RP5RPvsXedXiQ6e7z324-zb7clFeXV9fnny9apspJFz2YpGeMNV5VEDel3XVldVY7BFWxvktWoV1SQBbIuK152oQHZWkWprUgbEHvuy1Z3W9UBtk1eOfuWm2A8-blzwvXvdGfs7twwPTkthUdoscPgsEMPPNaXZDX1qaJWdUlgnx7HSmgsjqox--ge9D-s4ZnuOZwtgQXOTKb6lmhhSitS9LIPgniJy24hcjsj9isjJPPTxbxsvI78zyYDYAim3xiXFP3__R_YRMcmcOA</recordid><startdate>20190401</startdate><enddate>20190401</enddate><creator>Delos Santos, Rowena</creator><creator>Rossi, Ana</creator><creator>Coyne, Daniel</creator><creator>Maw, Thin Thin</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7QO</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8844-6925</orcidid></search><sort><creationdate>20190401</creationdate><title>Management of Post-transplant Hyperparathyroidism and Bone Disease</title><author>Delos Santos, Rowena ; Rossi, Ana ; Coyne, Daniel ; Maw, Thin Thin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-d3c3a7258a1601a6bb9688c71d19b712b5d5ebe4009d152bf3804f95e5dbe5703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Bone diseases</topic><topic>Bone Diseases - etiology</topic><topic>Bone Diseases - prevention & control</topic><topic>Bone Diseases - therapy</topic><topic>Calciferol</topic><topic>Calcimimetic Agents - therapeutic use</topic><topic>Complications</topic><topic>Disease control</topic><topic>End-stage renal disease</topic><topic>Hemodialysis</topic><topic>Homeostasis</topic><topic>Humans</topic><topic>Hypercalcemia</topic><topic>Hyperparathyroidism</topic><topic>Hyperparathyroidism - etiology</topic><topic>Hyperparathyroidism - prevention & control</topic><topic>Hyperparathyroidism - therapy</topic><topic>Hyperparathyroidism, Secondary - etiology</topic><topic>Hypocalcemia</topic><topic>Immunoassay</topic><topic>Immunosuppressive agents</topic><topic>Internal Medicine</topic><topic>Kidney diseases</topic><topic>Kidney transplantation</topic><topic>Kidney Transplantation - adverse effects</topic><topic>Lead</topic><topic>Management</topic><topic>Medical personnel</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Parathyroid</topic><topic>Parathyroid gland</topic><topic>Parathyroidectomy</topic><topic>Patients</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacotherapy</topic><topic>Side effects</topic><topic>Surgery</topic><topic>Survival</topic><topic>Therapy in Practice</topic><topic>Transplantation</topic><topic>Transplantation, Homologous</topic><topic>Transplants & implants</topic><topic>Treatment Outcome</topic><topic>Vitamin D</topic><topic>Vitamin D - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Delos Santos, Rowena</creatorcontrib><creatorcontrib>Rossi, Ana</creatorcontrib><creatorcontrib>Coyne, Daniel</creatorcontrib><creatorcontrib>Maw, Thin Thin</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Drugs (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Delos Santos, Rowena</au><au>Rossi, Ana</au><au>Coyne, Daniel</au><au>Maw, Thin Thin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of Post-transplant Hyperparathyroidism and Bone Disease</atitle><jtitle>Drugs (New York, N.Y.)</jtitle><stitle>Drugs</stitle><addtitle>Drugs</addtitle><date>2019-04-01</date><risdate>2019</risdate><volume>79</volume><issue>5</issue><spage>501</spage><epage>513</epage><pages>501-513</pages><issn>0012-6667</issn><issn>1179-1950</issn><eissn>1179-1950</eissn><abstract>Significant advances in immunosuppressive therapies have been made in renal transplantation, leading to increased allograft and patient survival. Despite improvement in overall patient survival, patients continue to require management of persistent post-transplant hyperparathyroidism. Medications that treat persistent hyperparathyroidism include vitamin D, vitamin D analogues, and calcimimetics. Medication side effects such as hypocalcemia or hypercalcemia, and adynamic bone disease, may lead to a decrease in the drugs. When medical management fails to control persistent post-transplant hyperparathyroidism, treatment is a parathyroidectomy. Surgical techniques are not uniform between centers and surgeons. Undergoing the surgery may include a subtotal technique or a technique including total parathyroid gland resection with partial heterotopic gland reimplantation. In addition, there are possible post-surgical complications. The ideal treatment for persistent post-transplant hyperparathyroidism is the treatment and prevention of the condition while patients are being managed for their late-stage chronic kidney disease and end-stage renal disease.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>30811012</pmid><doi>10.1007/s40265-019-01074-4</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-8844-6925</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-6667 |
| ispartof | Drugs (New York, N.Y.), 2019-04, Vol.79 (5), p.501-513 |
| issn | 0012-6667 1179-1950 1179-1950 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6439149 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Bone diseases Bone Diseases - etiology Bone Diseases - prevention & control Bone Diseases - therapy Calciferol Calcimimetic Agents - therapeutic use Complications Disease control End-stage renal disease Hemodialysis Homeostasis Humans Hypercalcemia Hyperparathyroidism Hyperparathyroidism - etiology Hyperparathyroidism - prevention & control Hyperparathyroidism - therapy Hyperparathyroidism, Secondary - etiology Hypocalcemia Immunoassay Immunosuppressive agents Internal Medicine Kidney diseases Kidney transplantation Kidney Transplantation - adverse effects Lead Management Medical personnel Medicine Medicine & Public Health Parathyroid Parathyroid gland Parathyroidectomy Patients Pharmacology/Toxicology Pharmacotherapy Side effects Surgery Survival Therapy in Practice Transplantation Transplantation, Homologous Transplants & implants Treatment Outcome Vitamin D Vitamin D - therapeutic use |
| title | Management of Post-transplant Hyperparathyroidism and Bone Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T18%3A16%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20Post-transplant%20Hyperparathyroidism%20and%20Bone%20Disease&rft.jtitle=Drugs%20(New%20York,%20N.Y.)&rft.au=Delos%20Santos,%20Rowena&rft.date=2019-04-01&rft.volume=79&rft.issue=5&rft.spage=501&rft.epage=513&rft.pages=501-513&rft.issn=0012-6667&rft.eissn=1179-1950&rft_id=info:doi/10.1007/s40265-019-01074-4&rft_dat=%3Cproquest_pubme%3E2186623738%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2258090627&rft_id=info:pmid/30811012&rfr_iscdi=true |